<DOC>
	<DOCNO>NCT00184548</DOCNO>
	<brief_summary>This trial conduct globally . The purpose trial evaluate activate recombinant human factor VII ( eptacog alfa ( activate ) ) safe effective severely injured trauma patient assess mortality morbidity . Please note trial trial F7TRAUMA-1648 ( NCT00323570 ) merge .</brief_summary>
	<brief_title>Evaluation Recombinant Factor VIIa Patients With Severe Bleeding</brief_title>
	<detailed_description>The decision discontinue F7TRAUMA-1711 trial due safety concern . The result pre-planned futility analysis perform June 2008 predict low likelihood reach successful outcome primary efficacy endpoint end trial consequence , company decide close trial juncture .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Trauma injury ( blunt and/or penetrate ) evidence active hemorrhage ( torso and/or proximal low extremity ) refractory blood component therapy surgical haemostatic procedure time randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>